Cargando…
Relaxin inhibits cardiac fibrosis and endothelial–mesenchymal transition via the Notch pathway
BACKGROUND: Relaxin (RLX) can prevent cardiac fibrosis. We aimed to investigate the possible mechanism and signal transduction pathway of RLX inhibiting cardiac fibrosis. METHODS: Isoproterenol (5 mg·kg(−1)·d(−1)) was used to establish the cardiac fibrosis model in rats, which were administered RLX....
Autores principales: | Zhou, X, Chen, X, Cai, JJ, Chen, LZ, Gong, YS, Wang, LX, Gao, Z, Zhang, HQ, Huang, WJ, Zhou, H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541540/ https://www.ncbi.nlm.nih.gov/pubmed/26316699 http://dx.doi.org/10.2147/DDDT.S85399 |
Ejemplares similares
-
Relaxin inhibits cardiac fibrosis and endothelial–mesenchymal transition via the Notch pathway [Corrigendum]
Publicado: (2017) -
Interplay between BMP2 and Notch signaling in endothelial-mesenchymal transition: implications for cardiac fibrosis
por: Docshin, Pavel, et al.
Publicado: (2023) -
Relaxin inhibits renal fibrosis and the epithelial-to-mesenchymal transition via the Wnt/β-catenin signaling pathway
por: Feiteng, Chen, et al.
Publicado: (2022) -
Relaxin Prevents Cardiac Fibroblast-Myofibroblast Transition via Notch-1-Mediated Inhibition of TGF-β/Smad3 Signaling
por: Sassoli, Chiara, et al.
Publicado: (2013) -
Trimetazidine Reduces Cardiac Fibrosis in Rats by Inhibiting NOX2-Mediated Endothelial-to-Mesenchymal Transition
por: Chen, Xingxing, et al.
Publicado: (2022)